PASG Reports $23.3M R&D Spend, $46.3M Cash, Advances PBFT02 Trial, Targets 1H 2026 Data Release
Passage Bio, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $5.85
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS